問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鍾牧圻

Recruiting

List

5Cases

2024-03-01 - 2027-12-31

Phase III

Active
A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function

  • Condition/Disease

    Heart Failure

  • Test Drug

    capsule

Participate Sites
21Sites

Not yet recruiting11Sites

Recruiting10Sites

2022-01-05 - 2029-11-11

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-12-30 - 2031-06-30

Phase II

Active
THE RETIRE TRIAL: A RANDOMIZED PHASE 2 TRIAL OF ADOPTIVE THERAPY WITH TREG ADOPTIVE CELL TRANSFER (TRACT) TO PREVENT REJECTION IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS

  • Condition/Disease

    Kidney Transplantation

  • Test Drug

    TRK-001

Participate Sites
4Sites

Recruiting4Sites

2022-10-01 - 2024-03-11

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-03-26 - 2023-02-06

Phase III

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

  • Condition/Disease

    Immunoglobulin A nephropathy

  • Test Drug

    Nefecon™

Participate Sites
3Sites

Recruiting3Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB